Normalized Ratio of APCR Measured by Different Assays
Assay . | Patient’s Samples* . | Homozygous FV Q506 Individual . | Normal Samples . | ||
---|---|---|---|---|---|
(1993) . | (1995) . | (1998) . | |||
Chromogenix-Coatest | |||||
No dilution | 0.50 | ND | 0.52 | 0.50 | >0.72 |
1:5 dilution in Vdp | ND | 0.56 | 0.80 | 0.44 | >0.70 |
1:10 dilution in Vdp | 0.82 | 0.77 | ND | ND | >0.72 |
Gradipore-PCl | |||||
No dilution | ND | ND | 0.52 | 0.43 | >0.73 |
1:5 dilution in Vdp | ND | 0.50 | 0.75 | 0.45 | >0.80 |
Gradipore-FV Leiden | |||||
No dilution | ND | ND | 0.34 | 0.26 | ND |
1:5 dilution in Vdp | ND | ND | 0.79 | 0.33 | ND |
1:10 dilution in Vdp | ND | ND | 0.84 | 0.33 | ND |
Behring-ProC Global | |||||
No dilution | ND | 0.50 | 0.41 | 0.38 | ND |
1:5 dilution in Vdp | ND | ND | 0.81 | 0.44 | ND |
1:10 dilution in Vdp | ND | ND | 0.87 | 0.50 | ND |
Assay . | Patient’s Samples* . | Homozygous FV Q506 Individual . | Normal Samples . | ||
---|---|---|---|---|---|
(1993) . | (1995) . | (1998) . | |||
Chromogenix-Coatest | |||||
No dilution | 0.50 | ND | 0.52 | 0.50 | >0.72 |
1:5 dilution in Vdp | ND | 0.56 | 0.80 | 0.44 | >0.70 |
1:10 dilution in Vdp | 0.82 | 0.77 | ND | ND | >0.72 |
Gradipore-PCl | |||||
No dilution | ND | ND | 0.52 | 0.43 | >0.73 |
1:5 dilution in Vdp | ND | 0.50 | 0.75 | 0.45 | >0.80 |
Gradipore-FV Leiden | |||||
No dilution | ND | ND | 0.34 | 0.26 | ND |
1:5 dilution in Vdp | ND | ND | 0.79 | 0.33 | ND |
1:10 dilution in Vdp | ND | ND | 0.84 | 0.33 | ND |
Behring-ProC Global | |||||
No dilution | ND | 0.50 | 0.41 | 0.38 | ND |
1:5 dilution in Vdp | ND | ND | 0.81 | 0.44 | ND |
1:10 dilution in Vdp | ND | ND | 0.87 | 0.50 | ND |
Abbreviations: ND, not done; Vdp, Factor V deficient plasma.
All samples were taken when patient received enoxaparine. Baseline clotting times (without APC) were within normal range in all assay systems.